
  
    
      
        Introduction_NNP
        Nausea_NN and_CC vomiting_NN during_IN pregnancy_NN (_( NVP_NNP )_) affects_VBZ up_IN to_TO
        80_CD %_NN of_IN all_DT pregnant_JJ women_NNS ,_, and_CC has_VBZ a_DT significant_JJ impact_NN on_IN
        the_DT quality_NN of_IN life_NN of_IN those_DT who_WP experience_VBP it_PRP [_NN 1_CD 2_CD ]_NN ._.
        The_DT effects_NNS can_MD range_VB from_IN mild_JJ nausea_NN to_TO more_RBR severe_JJ forms_NNS
        such_JJ as_IN 
        hyperemesis_NNS gravidarum_NN ,_, which_WDT is_VBZ
        characterized_VBN by_IN an_DT intractable_JJ nausea_NN and_CC vomiting_NN so_RB
        severe_JJ that_IN it_PRP can_MD lead_VB to_TO hospitalization_NN ._. Although_IN only_RB
        0_CD ._. 3_CD to_TO 3_CD %_NN of_IN pregnant_JJ women_NNS are_VBP diagnosed_VBN with_IN 
        hyperemesis_NNS gravidarum_NN [_NN 3_CD ]_NN ,_, less_RBR
        severe_JJ forms_NNS of_IN NVP_NNP exert_VB a_DT significant_JJ impact_NN on_IN the_DT
        quality_NN of_IN life_NN of_IN those_DT affected_VBN [_NN 1_CD ]_NN ._. In_IN one_CD study_NN ,_,
        close_RB to_TO 50_CD %_NN of_IN employed_VBN women_NNS reported_VBD reduced_VBN work_NN
        efficiency_NN due_JJ to_TO NVP_NNP ,_, with_IN as_RB many_JJ as_IN 25_CD -_: 66_CD %_NN of_IN women_NNS
        actually_RB requiring_VBG time_NN off_IN work_NN ._. Furthermore_RB ,_, almost_RB 50_CD %_NN
        of_IN women_NNS reported_VBD that_IN their_PRP$ NVP_NNP negatively_RB affected_VBD their_PRP$
        relationship_NN with_IN their_PRP$ partner_NN as_RB well_RB as_IN having_VBG an_DT
        adverse_JJ effect_NN on_IN their_PRP$ partner_NN 's_POS day-to-day_JJ life_NN [_NN 4_CD ]_NN
        ._.
        There_EX are_VBP a_DT number_NN of_IN effective_JJ options_NNS available_JJ for_IN
        the_DT alleviation_NN of_IN NVP_NNP ,_, varying_VBG from_IN non-pharmacological_JJ
        strategies_NNS such_JJ as_IN diet_NN and_CC lifestyle_NN changes_NNS to_TO
        pharmacological_JJ treatments_NNS such_JJ as_IN Diclectin_NNP
        ®_NN (_( doxylamine_NN /_NN pyridoxine_NN )_) [_NN 5_CD ]_NN ,_, antihistamine_NN H_NNP 1_CD blockers_NNS
        [_NN 6_CD ]_NN ,_, phenothiazines_NNS [_NN 7_CD ]_NN ,_, as_RB well_RB as_IN pyroxidine_NN
        (_( vitamin_NN B_NNP 6_CD )_) alone_RB [_NN 3_CD 8_CD ]_NN ._. The_DT thalidomide_NN tragedy_NN of_IN the_DT
        1960_CD 's_POS as_RB well_RB as_IN the_DT Bendectin_NNP ®_NN unfounded_JJ scare_NN of_IN the_DT mid_JJ
        1980_CD 's_POS [_NN 9_CD 10_CD ]_NN has_VBZ caused_VBN women_NNS with_IN NVP_NNP to_TO look_VB on_IN
        drug-based_JJ strategies_NNS with_IN great_JJ caution_NN due_JJ to_TO concerns_NNS
        over_IN the_DT perceived_VBN teratogenicity_NN of_IN these_DT drugs_NNS [_NN 4_CD 11_CD ]_NN ,_,
        even_RB when_WRB data_NNS exist_VBP documenting_VBG safety_NN [_NN 5_CD 9_CD 10_CD ]_NN ._.
        Accordingly_RB ,_, non-pharmacological_JJ strategies_NNS to_TO alleviate_VB
        NVP_NNP may_MD be_VB popular_JJ choices_NNS amongst_IN pregnant_JJ women_NNS ._. In_IN
        addition_NN to_TO dietary_JJ and_CC lifestyle_NN changes_NNS ,_, the_DT use_NN of_IN (_( CAM_NNP )_)
        to_TO alleviate_VB NVP_NNP may_MD be_VB an_DT attractive_JJ option_NN for_IN many_JJ
        women_NNS ._. The_DT perceived_VBN "_'' natural_JJ "_'' status_NN of_IN herbal_JJ products_NNS in_IN
        particular_JJ and_CC CAM_NNP in_IN general_JJ lead_NN many_JJ to_TO draw_VB the_DT
        conclusion_NN that_IN CAM_NNP therapies_NNS are_VBP not_RB associated_VBN with_IN
        adverse_JJ effects_NNS ._.
        The_DT use_NN of_IN CAM_NNP has_VBZ increased_VBN rapidly_RB in_IN the_DT last_JJ decade_NN
        [_NN 12_CD 13_CD ]_NN ._. Estimates_NNS of_IN the_DT prevalence_NN of_IN CAM_NNP use_NN in_IN the_DT
        United_NNP States_NNPS were_VBD as_RB high_JJ as_IN 42_CD %_NN in_IN 1997_CD ,_, with_IN CAM_NNP use_NN
        particularly_RB popular_JJ among_IN women_NNS of_IN reproductive_JJ age_NN [_NN 12_CD
        13_CD ]_NN ._. In_IN addition_NN ,_, almost_RB half_NN of_IN women_NNS surveyed_VBN reported_VBD
        using_VBG CAM_NNP (_( 48_CD ._. 2_LS %_NN )_) [_NN 12_CD ]_NN ._. Consequently_RB ,_, the_DT possibility_NN
        that_IN pregnant_JJ women_NNS are_VBP using_VBG CAM_NNP to_TO alleviate_VB complaints_NNS
        such_JJ as_IN NVP_NNP is_VBZ quite_RB possible_JJ ,_, although_IN the_DT exact_JJ
        percentage_NN remains_VBZ unknown_JJ ._. The_DT use_NN of_IN CAM_NNP therapies_NNS among_IN
        pregnant_JJ women_NNS is_VBZ an_DT important_JJ but_CC little_RB studied_VBN issue_NN ._.
        One_CD study_NN assessing_VBG the_DT CAM_NNP prescribing_VBG patterns_NNS of_IN
        Nurse-_NNP Midwives_NNP in_IN North_NNP Carolina_NNP revealed_VBD that_IN almost_RB half_NN
        of_IN nurse-midwives_JJ surveyed_VBN recommended_VBD CAM_NNP therapies_NNS to_TO
        more_JJR than_IN 10_CD %_NN of_IN their_PRP$ patients_NNS [_NN 14_CD ]_NN ._. Another_DT study_NN of_IN
        women_NNS attending_VBG antepartum_NN visits_NNS revealed_VBD that_IN almost_RB 10_CD %_NN
        of_IN these_DT women_NNS reported_VBD using_VBG herbal_JJ supplements_NNS during_IN
        their_PRP$ pregnancy_NN ,_, with_IN 7_CD ._. 5_CD %_NN of_IN these_DT women_NNS using_VBG these_DT
        preparations_NNS on_IN a_DT weekly_JJ basis_NN [_NN 15_CD ]_NN ._. Furthermore_RB ,_, 13_CD ._. 5_LS %_NN
        of_IN these_DT women_NNS reported_VBD using_VBG other_JJ non-herbal_JJ CAM_NNP
        therapies_NNS ._. There_EX are_VBP a_DT handful_NN of_IN studies_NNS suggesting_VBG
        effective_JJ relief_NN of_IN NVP_NNP by_IN CAM_NNP therapies_NNS such_JJ as_IN ginger_NN [_NN 3_CD
        16_CD ]_NN ,_, manual_JJ acupuncture_NN [_NN 17_CD 18_CD ]_NN ,_, acupressure_NN [_NN 3_CD ]_NN and_CC
        vitamin_NN B_NNP 6_CD [_NN 3_CD 8_CD ]_NN ._. Nevertheless_RB ,_, there_EX is_VBZ little_JJ research_NN
        on_IN the_DT efficacy_NN and_CC safety_NN of_IN the_DT full_JJ range_NN of_IN CAM_NNP
        modalities_NNS used_VBN by_IN women_NNS to_TO alleviate_VB NVP_NNP ._. Furthermore_RB ,_,
        there_EX is_VBZ little_JJ information_NN about_IN the_DT types_NNS of_IN CAM_NNP
        treatments_NNS that_WDT are_VBP being_VBG used_VBN by_IN women_NNS experiencing_VBG NVP_NNP ,_,
        as_RB well_RB as_IN how_WRB they_PRP obtain_VBP information_NN about_IN potential_JJ CAM_NNP
        therapies_NNS Finally_RB ,_, the_DT degree_NN of_IN supervision_NN of_IN CAM_NNP use_NN in_IN
        this_DT population_NN is_VBZ not_RB well_RB defined_VBN ._.
        This_DT pilot_NN study_NN was_VBD undertaken_VBN to_TO investigate_VB the_DT
        prevalence_NN ,_, supervision_NN and_CC types_NNS of_IN CAM_NNP treatments_NNS used_VBN
        for_IN NVP_NNP by_IN women_NNS using_VBG the_DT NVP_NNP counseling_NN line_NN at_IN the_DT
        Motherisk_NNP Program_NNP located_VBN at_IN the_DT Hospital_NNP for_IN Sick_NNP Children_NNP
        in_IN Toronto_NNP ,_, Ontario_NNP ._.
      
      
        Patients_NNS and_CC methods_NNS
        Women_NNP receiving_VBG counseling_NN by_IN the_DT Motherisk_NNP Program_NNP NVP_NNP
        line_NN ,_, who_WP call_VBP us_PRP from_IN across_IN North_NNP America_NNP ,_, were_VBD asked_VBN
        whether_IN or_CC not_RB they_PRP wished_VBD to_TO complete_VB a_DT phone_NN survey_NN
        regarding_VBG their_PRP$ use_NN or_CC non-use_JJ of_IN CAM_NNP to_TO alleviate_VB their_PRP$
        NVP_NNP ._. The_DT questionnaire_NN was_VBD administered_VBN to_TO the_DT survey_NN
        participants_NNS either_CC directly_RB following_VBG the_DT counseling_NN
        session_NN or_CC at_IN a_DT later_JJ time_NN mutually_RB agreed_VBD upon_IN by_IN the_DT
        participant_NN and_CC the_DT interviewer_NN ._.
        Demographic_NNP data_NNS were_VBD collected_VBN for_IN all_DT of_IN the_DT survey_NN
        respondents_NNS including_VBG the_DT number_NN of_IN previous_JJ children_NNS ,_,
        previous_JJ experience_NN with_IN NVP_NNP ,_, pregnancy-related_JJ medication_NN
        as_RB well_RB as_IN any_DT adverse_JJ experiences_NNS related_VBN to_TO
        pregnancy-related_JJ medication_NN ._. In_IN addition_NN ,_, all_DT respondents_NNS
        were_VBD asked_VBN to_TO describe_VB the_DT severity_NN of_IN their_PRP$ NVP_NNP on_IN a_DT scale_NN
        of_IN 0_CD -_: 10_CD ,_, with_IN 10_CD being_VBG the_DT most_RBS severe_JJ ,_, as_RB well_RB as_IN whether_IN
        or_CC not_RB they_PRP had_VBD previously_RB used_VBN CAM_NNP ._. Survey_NN respondents_NNS who_WP
        reported_VBD non-use_JJ of_IN CAM_NNP to_TO alleviate_VB NVP_NNP were_VBD asked_VBN to_TO
        agree_VB or_CC disagree_VBP with_IN a_DT series_NN of_IN possible_JJ reasons_NNS why_WRB
        they_PRP did_VBD not_RB use_VB CAM_NNP to_TO alleviate_VB their_PRP$ NVP_NNP ._. The_DT level_NN of_IN
        agreement_NN was_VBD measured_VBN by_IN a_DT 5_CD -_: point_NN Likert_NNP Scale_NNP ,_, where_WRB 1_CD =_SYM
        strongly_RB disagree_VBP ,_, 2_CD =_SYM disagree_VBP somewhat_RB ,_, 3_CD =_SYM undecided_JJ ,_, 4_CD
        =_SYM somewhat_RB agree_VBP and_CC 5_CD =_SYM strongly_RB agree_VBP ._. Respondents_NNP who_WP
        reported_VBD using_VBG CAM_NNP to_TO alleviate_VB their_PRP$ NVP_NNP were_VBD asked_VBN which_WDT
        CAM_NNP therapies_NNS they_PRP had_VBD used_VBN ._. They_PRP were_VBD also_RB asked_VBN how_WRB they_PRP
        found_VBD out_IN about_IN CAM_NNP therapies_NNS ,_, and_CC whether_IN or_CC not_RB their_PRP$ CAM_NNP
        use_NN was_VBD supervised_VBN by_IN a_DT licensed_VBN health_NN care_NN practitioner_NN
        who_WP practiced_VBD CAM_NNP either_CC as_IN part_NN of_IN their_PRP$ practice_NN or_CC in_IN
        whole_NN ._. Users_NNS of_IN CAM_NNP were_VBD also_RB asked_VBN 9_CD possible_JJ reasons_NNS why_WRB
        they_PRP chose_VBD to_TO use_VB CAM_NNP to_TO alleviate_VB their_PRP$ NVP_NNP ,_, using_VBG the_DT
        same_JJ Likert_NNP Scale_NNP used_VBD for_IN non-_NN CAM_NNP users_NNS ._.
        The_DT demographic_JJ data_NN ,_, reported_VBD severity_NN of_IN NVP_NNP ,_, and_CC
        previous_JJ CAM_NNP use_NN were_VBD compared_VBN between_IN users_NNS and_CC non-users_JJ
        of_IN CAM_NNP ._. The_DT level_NN of_IN agreement_NN with_IN statements_NNS regarding_VBG
        CAM_NNP use_NN or_CC non-use_JJ was_VBD reported_VBN as_IN a_DT mean_NN Likert_NNP Scale_NNP
        value_NN plus_CC standard_JJ deviation_NN ._. Simple_NN numerical_JJ analysis_NN
        was_VBD used_VBN to_TO report_VB the_DT types_NNS of_IN CAM_NNP interventions_NNS used_VBN as_RB
        well_RB as_IN the_DT numbers_NNS and_CC types_NNS of_IN practitioners_NNS consulted_VBN
        and_CC source_NN used_VBN to_TO access_VB CAM_NNP information_NN ._.
      
      
        Results_NNS
        A_DT total_NN of_IN seventy_NN out_IN of_IN 110_CD women_NNS consented_VBD to_TO be_VB
        interviewed_VBN and_CC completed_VBD the_DT questionnaire_NN ._. 10_CD women_NNS
        refused_VBD to_TO participate_VB and_CC 30_CD were_VBD lost_VBN to_TO follow_VB up_RP ._. The_DT
        demographics_NNS of_IN the_DT women_NNS lost_VBD to_TO follow_VB up_RP did_VBD not_RB differ_VB
        significantly_RB from_IN the_DT respondents_NNS ._. Demographic_NNP
        characteristics_NNS of_IN the_DT questionnaire_NN respondents_NNS are_VBP
        summarized_VBD in_IN Table_NNP 1_CD ._. Almost_RB half_NN of_IN the_DT respondents_NNS were_VBD
        between_IN the_DT ages_NNS of_IN 30_CD -_: 34_CD ._. In_IN addition_NN ,_, the_DT majority_NN were_VBD
        married_VBN (_( or_CC living_VBG with_IN a_DT partner_NN )_) ,_, Caucasian_NNP ,_, had_VBD
        completed_VBN a_DT college_NN ,_, university_NN or_CC post-graduate_JJ degree_NN and_CC
        reported_VBD a_DT total_JJ household_NN income_NN of_IN $_$ 41_CD ,_, 000_CD (_( CDN_NNP )_) /_NN year_NN
        or_CC greater_JJR ._. Almost_RB half_NN were_VBD employed_VBN full-time_JJ and_CC
        one-third_NN identified_VBD themselves_PRP as_IN homemakers_NNS ._. Most_JJS survey_NN
        respondents_NNS indicated_VBD that_IN they_PRP had_VBD one_CD child_NN or_CC less_JJR at_IN
        time_NN of_IN interview_NN and_CC two-thirds_NNS reported_VBD having_VBG
        experienced_VBN nausea_NN and_CC vomiting_NN in_IN a_DT previous_JJ
        pregnancy_NN ._.
        Half_NN of_IN the_DT respondents_NNS reported_VBD using_VBG pharmaceutical_JJ
        drugs_NNS during_IN their_PRP$ pregnancy_NN ,_, with_IN Diclectin_NNP ®_NN being_VBG the_DT
        most_RBS commonly_RB used_VBN medication_NN (_( used_VBN by_IN two-thirds_NNS of_IN those_DT
        who_WP indicated_VBD that_IN they_PRP had_VBD taken_VBN medication_NN )_) ._. More_JJR than_IN
        half_NN of_IN all_DT Diclectin_NNP ®_NN users_NNS reported_VBD an_DT adverse_JJ effect_NN
        from_IN the_DT drug_NN ,_, namely_RB drowsiness_NNS ,_, with_IN three_CD women_NNS also_RB
        reporting_VBG irritability_NN and_CC dry_JJ mouth_NN ._. Most_JJS of_IN the_DT
        respondents_NNS reported_VBD that_IN their_PRP$ family_NN physician_NN or_CC
        obstetrician_NN was_VBD their_PRP$ primary_JJ obstetric_JJ caregiver_NN at_IN the_DT
        time_NN of_IN the_DT interview_NN ._.
        Almost_RB two-thirds_NNS (_( 61_CD ._. 2_LS %_NN )_) of_IN the_DT survey_NN respondents_NNS
        reported_VBD using_VBG CAM_NNP to_TO alleviate_VB NVP_NNP ._. The_DT three_CD most_RBS common_JJ
        types_NNS of_IN CAM_NNP used_VBD are_VBP summarized_VBD in_IN Table_NNP 2_CD and_CC were_VBD :_: ginger_NN
        teas_NNS or_CC tablets_NNS ,_, accupressure_NN /_NN seabands_NNS ,_, and_CC Vitamin_NNP B_NNP 6_CD )_) ._.
        The_DT most_RBS common_JJ information_NN sources_NNS for_IN respondents_NNS about_IN
        the_DT use_NN of_IN CAM_NNP for_IN NVP_NNP are_VBP also_RB summarized_VBD in_IN Table_NNP 2_CD and_CC
        were_VBD :_: family_NN and_CC friends_NNS ,_, women_NNS 's_POS health_NN centres_NNS ,_, or_CC
        pregnancy_NN counseling_NN lines_NNS ,_, CAM_NNP practitioners_NNS followed_VBN by_IN
        their_PRP$ doctor_NN or_CC pharmacist_NN ._. The_DT most_RBS commonly_RB consulted_VBN CAM_NNP
        practitioners_NNS were_VBD acupuncturists_NNS ,_, chiropractors_NNS ,_,
        homeopaths_NNS and_CC naturopaths_NNS ._. Only_RB 21_CD ._. 6_CD %_NN of_IN respondents_NNS
        consulted_VBN with_IN a_DT CAM_NNP practitioner_NN when_WRB using_VBG CAM_NNP to_TO
        alleviate_VB NVP_NNP ._. Furthermore_RB ,_, 20_CD ._. 7_CD %_NN of_IN CAM_NNP users_NNS reported_VBD
        mild_JJ adverse_JJ reactions_NNS associated_VBN with_IN using_VBG CAM_NNP to_TO
        alleviate_VB their_PRP$ NVP_NNP ._. The_DT most_RBS commonly_RB reported_VBD adverse_JJ
        experiences_NNS were_VBD the_DT intolerability_NN of_IN the_DT strong_JJ flavour_NN
        of_IN ginger_NN and_CC wrist_NN irritation_NN among_IN respondents_NNS who_WP used_VBD
        acupressure_NN wrist_NN bands_NNS ._.
        Survey_NN respondents_NNS were_VBD asked_VBN why_WRB they_PRP chose_VBD to_TO use_VB CAM_NNP
        to_TO alleviate_VB their_PRP$ NVP_NNP (_( table_NN 3_LS )_) and_CC were_VBD also_RB asked_VBN why_WRB
        they_PRP did_VBD not_RB use_VB CAM_NNP (_( table_NN 4_LS )_) ._. The_DT most_RBS common_JJ reason_NN
        given_VBN for_IN using_VBG CAM_NNP was_VBD :_: because_IN this_DT was_VBD not_RB really_RB a_DT
        "_'' drug_NN "_'' and_CC it_PRP was_VBD probably_RB safer_JJR to_TO use_VB in_IN pregnancy_NN than_IN a_DT
        pharmaceutical_JJ product_NN ._. The_DT most_RBS common_JJ reason_NN for_IN not_RB
        using_VBG CAM_NNP was_VBD :_: there_EX was_VBD not_RB enough_JJ information_NN about_IN the_DT
        use_NN of_IN these_DT products_NNS ._.
        The_DT level_NN of_IN education_NN ,_, income_NN ,_, severity_NN of_IN NVP_NNP ,_, and_CC
        previous_JJ CAM_NNP use_NN were_VBD assessed_VBN as_IN possible_JJ predictors_NNS of_IN
        CAM_NNP use_NN in_IN survey_NN respondents_NNS ._. Out_IN of_IN these_DT four_CD factors_NNS
        assessed_VBN ,_, only_RB NVP_NNP severity_NN was_VBD associated_VBN with_IN CAM_NNP usage_NN
        to_TO alleviate_VB NVP_NNP :_: Table_NNP 5_CD
      
      
        Discussion_NNP
        This_DT study_NN was_VBD undertaken_VBN to_TO investigate_VB the_DT prevalence_NN ,_,
        types_NNS of_IN CAM_NNP treatments_NNS used_VBN and_CC supervision_NN if_IN any_DT ,_, of_IN the_DT
        treatment_NN of_IN nausea_NN and_CC vomiting_NN of_IN pregnancy_NN by_IN women_NNS
        using_VBG the_DT NVP_NNP counseling_NN line_NN at_IN the_DT Motherisk_NNP Program_NNP at_IN
        the_DT Hospital_NNP for_IN Sick_NNP Children_NNP in_IN Toronto_NNP ,_, Ontario_NNP ,_, Canada_NNP ._.
        Because_IN the_DT use_NN of_IN CAM_NNP has_VBZ become_VBN more_RBR prevalent_JJ in_IN the_DT
        general_JJ population_NN in_IN recent_JJ years_NNS ,_, coupled_VBN with_IN the_DT fact_NN
        that_IN 70_CD %_NN of_IN all_DT pregnant_JJ women_NNS suffer_VBP from_IN NVP_NNP ,_, one_PRP might_MD
        be_VB able_JJ to_TO extrapolate_NN these_DT results_NNS to_TO the_DT general_JJ
        population_NN of_IN women_NNS who_WP suffer_VBP from_IN NVP_NNP ,_, but_CC did_VBD not_RB call_VB
        the_DT NVP_NNP helpline_NN ._. It_PRP is_VBZ a_DT fact_NN that_IN women_NNS who_WP call_VBP the_DT NVP_NNP
        helpline_NN do_VBP have_VBP a_DT higher_JJR SES_NNP status_NN and_CC it_PRP is_VBZ known_VBN that_IN
        SES_NNP status_NN has_VBZ an_DT impact_NN on_IN the_DT use_NN CAM_NNP ._. (_( 19_CD )_) However_RB ,_, there_EX
        was_VBD no_DT correlation_NN between_IN the_DT use_NN of_IN CAM_NNP and_CC higher_JJR SES_NNP in_IN
        our_PRP$ study_NN ,_, the_DT only_JJ factor_NN that_WDT predicted_VBD the_DT use_NN of_IN CAM_NNP
        was_VBD the_DT severity_NN of_IN NVP_NNP ._. This_DT finding_VBG may_MD appear_VB to_TO be_VB
        suprising_VBG ,_, however_RB it_PRP was_VBD not_RB to_TO us_PRP at_IN the_DT Motherisk_NNP NVP_NNP
        Helpline_NNP ,_, because_IN over_IN the_DT years_NNS ,_, many_JJ women_NNS have_VBP told_VBN us_PRP
        that_IN NVP_NNP can_MD be_VB so_RB debilitating_JJ that_IN they_PRP will_MD try_VB just_RB
        about_IN anything_NN to_TO alleviate_VB their_PRP$ symptoms_NNS ._.
        Our_PRP$ results_NNS showed_VBD that_IN CAM_NNP was_VBD used_VBN by_IN almost_RB
        two-thirds_NNS of_IN our_PRP$ surveyed_VBN population_NN of_IN women_NNS experiencing_VBG
        NVP_NNP ._. Even_RB the_DT women_NNS who_WP did_VBD not_RB use_VB CAM_NNP felt_VBD they_PRP would_MD
        have_VB if_IN there_EX was_VBD more_JJR information_NN on_IN the_DT safety_NN during_IN
        pregnancy_NN ._. We_PRP also_RB found_VBD that_IN CAM_NNP use_NN in_IN this_DT population_NN is_VBZ
        largely_RB unsupervised_JJ ,_, with_IN most_JJS women_NNS getting_VBG information_NN
        from_IN their_PRP$ family_NN and_CC friends_NNS and_CC buying_VBG the_DT products_NNS
        directly_RB from_IN herbal_JJ stores_NNS ._. Women_NNP who_WP used_VBD CAM_NNP reported_VBD
        that_IN it_PRP made_VBD them_PRP feel_VBP more_JJR in_IN control_NN of_IN their_PRP$ health_NN care_NN
        decisions_NNS and_CC that_IN they_PRP perceived_VBD it_PRP would_MD be_VB safer_JJR than_IN
        pharmaceutical_JJ products_NNS ._.
        The_DT population_NN at_IN large_JJ has_VBZ probably_RB been_VBN exposed_VBN to_TO the_DT
        use_NN of_IN CAM_NNP through_IN media_NNS ,_, such_JJ as_IN television_NN and_CC magazines_NNS
        as_RB well_RB as_IN the_DT internet_NN ,_, which_WDT is_VBZ present_JJ in_IN almost_RB half_NN of_IN
        the_DT homes_NNS in_IN the_DT country_NN and_CC may_MD feel_VB that_IN because_IN of_IN this_DT
        they_PRP are_VBP knowledgable_JJ about_IN this_DT form_NN of_IN medicine_NN ._. Many_JJ
        people_NNS today_NN feel_VBP that_IN they_PRP would_MD like_VB to_TO be_VB more_JJR in_IN
        control_NN of_IN their_PRP$ own_JJ health_NN care_NN and_CC perceive_VBP that_IN CAM_NNP
        allows_VBZ this_DT ,_, as_IN neither_DT a_DT prescription_NN nor_CC physician_NN visit_NN
        is_VBZ required_VBN for_IN the_DT use_NN of_IN these_DT treatments_NNS ._.
        Natural_NNP is_VBZ often_RB perceived_VBN as_IN "_'' safe_JJ "_'' which_WDT is_VBZ not_RB
        necessarily_RB always_RB the_DT case_NN ._. This_DT perception_NN can_MD be_VB
        especially_RB true_JJ with_IN pregnant_JJ women_NNS ,_, who_WP wish_VBP to_TO protect_VB
        their_PRP$ fetuses_NNS from_IN "_'' harmful_JJ things_NNS "_'' such_JJ as_IN pharmaceutical_JJ
        products_NNS ._. This_DT is_VBZ born_VBN out_IN by_IN the_DT fact_NN that_IN many_JJ women_NNS call_VBP
        our_PRP$ general_JJ Motherisk_NNP Program_NNP information_NN line_NN asking_VBG about_IN
        the_DT safety_NN of_IN other_JJ CAM_NNP use_NN during_IN pregnancy_NN ,_, as_IN they_PRP feel_VBP
        this_DT would_MD be_VB a_DT safer_JJR option_NN for_IN their_PRP$ baby_NN ._. The_DT number_NN of_IN
        calls_NNS about_IN the_DT use_NN of_IN CAM_NNP in_IN general_JJ during_IN pregnancy_NN has_VBZ
        increased_VBN dramatically_RB over_IN the_DT past_JJ few_JJ years_NNS reflecting_VBG
        the_DT population_NN 's_POS interest_NN in_IN this_DT form_NN of_IN treatment_NN ._.
        Unfortunately_RB ,_, we_PRP have_VBP to_TO inform_VB the_DT callers_NNS that_IN there_EX is_VBZ
        scant_JJ research_NN on_IN the_DT use_NN and_CC safety_NN of_IN CAM_NNP during_IN
        pregnancy_NN ,_, whereas_IN there_EX are_VBP quite_RB a_DT substantial_JJ number_NN of_IN
        studies_NNS in_IN the_DT current_JJ literature_NN regarding_VBG the_DT use_NN and_CC
        safety_NN of_IN pharmaceutical_JJ products_NNS during_IN pregnancy_NN ._.
        The_DT limitation_NN of_IN this_DT study_NN is_VBZ primarily_RB the_DT small_JJ
        sample_NN size_NN ,_, as_IN seventy_NN women_NNS are_VBP a_DT low_JJ number_NN for_IN a_DT survey_NN
        of_IN this_DT kind_NN ._. It_PRP is_VBZ also_RB not_RB a_DT population_NN based_VBD study_NN as_IN
        women_NNS who_WP call_VBP our_PRP$ helpline_NN do_VBP differ_VB in_IN some_DT ways_NNS from_IN the_DT
        general_JJ population_NN ._.
        In_IN summary_NN ,_, a_DT significant_JJ amount_NN of_IN women_NNS are_VBP using_VBG CAM_NNP
        in_IN pregnancy_NN for_IN the_DT treatment_NN of_IN NVP_NNP ,_, despite_IN the_DT lack_NN of_IN
        safety_NN or_CC efficacy_NN data_NNS and_CC often_RB without_IN any_DT supervision_NN
        from_IN a_DT knowledgable_JJ practitioner_NN ._. Further_RB research_NN in_IN this_DT
        field_NN may_MD allow_VB pregnant_JJ women_NNS more_JJR options_NNS in_IN treating_VBG
        this_DT very_RB common_JJ conditon_NN of_IN pregnancy_NN ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Authors_NNP '_'' contributions_NNS
        Author_NN 1_CD conceived_VBD the_DT study_NN and_CC participated_VBD in_IN writing_VBG
        the_DT paper_NN
        Author_NN 2_CD participated_VBD in_IN writing_VBG the_DT paper_NN
        Author_NN 3_CD participated_VBD in_IN study_NN design_NN and_CC carried_VBD out_RP
        the_DT study_NN
        Author_NN 4_CD participated_VBD in_IN study_NN design_NN
        Author_NN 5_CD participated_VBD in_IN study_NN design_NN ,_, writing_NN of_IN paper_NN
        and_CC overall_JJ coordination_NN ._.
      
    
  
